Professor Adrian Brunt's Outputs (8)

FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015) (2018)
Journal Article
Brunt, A., Haviland, J., Sydenham, M., Algurafi, H., Alhasso, A., Bliss, P., Bloomfield, D., Emson, M., Goodman, A., Harnett, A., Passant, H., Tsang, Y., Wheatley, D., Bliss, J., & Yarnold, J. (2018). FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology - Biology - Physics, 102(5), 1603 -1604. https://doi.org/10.1016/j.ijrobp.2018.08.049

Conference abstract.

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial (2018)
Journal Article
Velikova, G., Jane Williams, L., Willis, S., Michael Dixon, J., Loncaster, J., Hatton, M., Clarke, J., Kunkler, P. I. H., H Kunkler, I., S Russell, N., trial UK investigators, M. S., Alhasso, A., Adamson, D., Algurafi, H., Allerton, R., Anandadas, C., Bahl, A., Barraclough, L., Barrett-Lee, P., Barthakur, U., …Yuille, F. (2018). Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial. Lancet Oncology, 19(11), 1516 - 1529. https://doi.org/10.1016/s1470-2045%2818%2930515-1

Background
Postmastectomy radiotherapy in patients with four or more positive axillary nodes reduces breast cancer mortality, but its role in patients with one to three involved nodes is controversial. We assessed the effects of postmastectomy radio... Read More about Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial (2018)
Journal Article
Corrie, P., Marshall, A., Nathan, P., Lorigan, P., Gore, M., Tahir, S., Faust, G., Kelly, C., Marples, M., Danson, S., Marshall, E., Houston, S., Board, R., Waterston, A., Nobes, J., Harries, M., Kumar, S., Goodman, A., Dalgleish, A., Martin-Clavijo, A., …Coltart, R. (2018). Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Annals of oncology, 29(8), 1843 -1852. https://doi.org/10.1093/annonc/mdy229

Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recur... Read More about Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial (2018)
Presentation / Conference Contribution
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, M., Nemsadze, G., Baird, R., Hee Park, Y., Hall, P., Perren, T., Stein, R. C., László, M., Ferrero, J.-M., Phillips, M., Conibear, J., Sarker, S.-J., Prendergast, A., Cartwright, H., Mousa, K., & Turner, N. C. (2018, June). AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. Presented at 2018 ASCO Annual Meeting I, Chicago, IL, USA

Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-l... Read More about AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.

Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. (2018)
Journal Article
Winters, Z. E., Horsnell, J., Elvers, K. T., Maxwell, A. J., Jones, L. J., Shaaban, A. M., Schmid, P., Williams, N. R., Beswick, A., Greenwood, R., Ingram, J. C., Saunders, C., Vaidya, J. S., Esserman, L., Jatoi, I., & Brunt, A. M. (2018). Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers. BJS Open, 2(4), 162 - 174. https://doi.org/10.1002/bjs5.53

Background: The clinical effectiveness of treating ipsilateral multifocal (MF) and multicentric (MC) breast cancers using breast-conserving surgery (BCS) compared with the standard of mastectomy is uncertain. Inconsistencies relate to definitions, in... Read More about Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers..

Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification (2018)
Presentation / Conference Contribution
Fullagar, A., Sodhi, L., Pillai, S., & Brunt, A. (2018, April). Radioactive Phosphorous (P32) Leukomogenic and Oncogenic Risk Stratification. Presented at 58th Annual Scientific Meeting of the British-Society-for-Haematology, Liverpool, UK

Meeting abstract

FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects (2018)
Presentation / Conference Contribution
Brunt, A., Haviland, J., Sydenham, M., Al-hasso, A., Bloomfield, D., Chan, C., Churn, M., Cleator, S., Coles, C., Emson, M., Goodman, A., Griffin, C., Harnett, A., Hopwood, P., Kirby, A., Kirwan, C., Morris, C., Sawyer, E., Somaiah, N., Syndikus, I., …Yarnold, J. FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Presented at ESTRO 37, April 20-24, 2018, Barcelona, Spain

Meeting abstract.

Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience (2018)
Presentation / Conference Contribution
Yoganayagam, N., Tripathy, A., Exton, S., Rawet, T., Wu, K., Brunt, A., Gahir, D., & Jegannathen, A. (2018, March). Benefits in early use of eribulin in metastatic breast cancer: A 7-year UHNM experience. Poster presented at THE 11TH EUROPEAN BREAST CANCER CONFERENCE, Barcelona, Spain

Meeting abstract from 11th European Breast Cancer Conference (EBCC), Barcelona, Spain, Mar 21-23, 2018.